This Trial is Conducted in the United State of America. The Aim of This Trial is to Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2017
At a glance
- Drugs NN 9277 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2017 Planned End Date changed from 6 Sep 2017 to 25 Oct 2017.
- 04 Aug 2017 Planned primary completion date changed from 6 Sep 2017 to 25 Oct 2017.